Scholarlink

Background <p>Ewing sarcoma is a malignant small round-cell sarcoma of bone or soft tissue that is highly responsive to modern multimodal therapy and considered a highly curable disease in developed countries. However, survival remains poor in developing countries. This study aims to assess treatment patterns and survival outcomes of Ewing sarcoma at Tikur Anbessa Hospital.</p> Methods and materials <p>We conducted a retrospective study on all patients diagnosed with Ewing sarcoma at Tikur Anbessa Hospital between November 15, 2018, and November 15, 2023. Descriptive statistics and Kaplan–Meier survival analysis were used to analyze the data.</p> Result <p>The median age at diagnosis was 19&#xa0;years, with most of the patients (67.2%) in the age range of 8–25&#xa0;years. The main modality of treatment for localized disease was chemotherapy combined with surgery, whereas chemotherapy alone was used for metastatic disease. The Kaplan–Meier estimated 1-year and 3-year overall survival (OS) rates for the entire cohort were 96% and 68%, respectively, and the corresponding 1-year and 3-year event-free survival (EFS) rates were 70% and 40%, respectively. A sensitivity analysis treating loss to follow-up as events reduced the 3-year overall survival from 68% to 55% and the 3-year event-free survival from 40 to 33%. The 3-year OS and EFS rates were 89% and 76% for localized disease versus 10% and 0% for metastatic disease. This difference was statistically significant (log-rank <i>p</i> &lt; 0.001).</p> <p>Small tumor size (≤ 8&#xa0;cm), surgical intervention, and localized stage were associated with statistically significant improvements in OS and EFS, whereas pelvic location was associated with a poorer prognosis.</p> Conclusion <p>Ewing sarcoma at our institution mainly affects adolescents and young adults. Survival is poor, especially for metastatic disease, while localized tumors, smaller size, and surgery are associated with better survival. Therefore, early diagnosis and improved multimodal treatment are needed to improve survival.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment patterns and survival outcomes of Ewing sarcoma in Ethiopia: a five-year retrospective analysis from a tertiary hospital

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月1日

查看全文
  • Tegene Gizaw,
  • Adugna Fikadu,
  • Gashaw Arega,
  • Birhanu Tesfaye,
  • Damena Teshome,
  • Sonia Worku,
  • Feleke Hailemariam

摘要

Background

Ewing sarcoma is a malignant small round-cell sarcoma of bone or soft tissue that is highly responsive to modern multimodal therapy and considered a highly curable disease in developed countries. However, survival remains poor in developing countries. This study aims to assess treatment patterns and survival outcomes of Ewing sarcoma at Tikur Anbessa Hospital.

Methods and materials

We conducted a retrospective study on all patients diagnosed with Ewing sarcoma at Tikur Anbessa Hospital between November 15, 2018, and November 15, 2023. Descriptive statistics and Kaplan–Meier survival analysis were used to analyze the data.

Result

The median age at diagnosis was 19 years, with most of the patients (67.2%) in the age range of 8–25 years. The main modality of treatment for localized disease was chemotherapy combined with surgery, whereas chemotherapy alone was used for metastatic disease. The Kaplan–Meier estimated 1-year and 3-year overall survival (OS) rates for the entire cohort were 96% and 68%, respectively, and the corresponding 1-year and 3-year event-free survival (EFS) rates were 70% and 40%, respectively. A sensitivity analysis treating loss to follow-up as events reduced the 3-year overall survival from 68% to 55% and the 3-year event-free survival from 40 to 33%. The 3-year OS and EFS rates were 89% and 76% for localized disease versus 10% and 0% for metastatic disease. This difference was statistically significant (log-rank p < 0.001).

Small tumor size (≤ 8 cm), surgical intervention, and localized stage were associated with statistically significant improvements in OS and EFS, whereas pelvic location was associated with a poorer prognosis.

Conclusion

Ewing sarcoma at our institution mainly affects adolescents and young adults. Survival is poor, especially for metastatic disease, while localized tumors, smaller size, and surgery are associated with better survival. Therefore, early diagnosis and improved multimodal treatment are needed to improve survival.